RBC Capital Starts Five Prime Therapeutics (FPRX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts FPRX Hot Sheet
Price: $38.00 --0%
Rating Summary:
9 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
9 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
RBC Capital initiates coverage on Five Prime Therapeutics (NASDAQ: FPRX) with a Outperform rating and a price target of $41.00.
For an analyst ratings summary and ratings history on Five Prime Therapeutics click here. For more ratings news on Five Prime Therapeutics click here.
Shares of Five Prime Therapeutics closed at $35.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sherwin-Williams (SHW) PT Lowered to $392 at RBC Capital
- BNP Paribas Exane Starts BellRing Brands (BRBR) at Outperform
- Cantor Fitzgerald Starts Ovid Therapeutics Inc (OVID) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
